Impact of 21‐Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study

BACKGROUND. The ROXANE Italian prospective study evaluated the impact of the 21‐gene Recurrence Score (RS) results on adjuvant treatment decision for patients with early breast cancer. MATERIALS AND METHODS. Nine centers participated. Physicians used the RS test whenever unsure about adjuvant treatm...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Dieci, Maria Vittoria, Guarneri, Valentina, Zustovich, Fable, Mion, Marta, Morandi, Paolo, Bria, Emilio, Merlini, Laura, Bullian, Pierluigi, Oliani, Cristina, Gori, Stefania, Giarratano, Tommaso, Orvieto, Enrico, Griguolo, Gaia, Michieletto, Silvia, Saibene, Tania, Del Bianco, Paola, De Salvo, Gian Luca, Conte, PierFranco
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2019
Matèries:
Breast Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6853101/
https://ncbi.nlm.nih.gov/pubmed/31152079
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0103
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars